Shares of Rockwell Medical Inc (NASDAQ:RMTI) have been assigned an average rating of “Buy” from the six brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $11.00.

Several analysts recently commented on the company. HC Wainwright set a $12.00 price objective on Rockwell Medical and gave the stock a “buy” rating in a report on Tuesday, May 28th. Cantor Fitzgerald assumed coverage on Rockwell Medical in a report on Monday, June 24th. They issued an “overweight” rating and a $11.00 price objective for the company. Piper Jaffray Companies assumed coverage on Rockwell Medical in a report on Monday, June 24th. They issued an “overweight” rating and a $10.00 price objective for the company. Ifs Securities lowered Rockwell Medical from a “strong-buy” rating to an “outperform” rating in a report on Wednesday, June 19th. Finally, Zacks Investment Research lowered Rockwell Medical from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd.

In related news, CEO Stuart M. Paul purchased 10,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was acquired at an average price of $2.97 per share, with a total value of $29,700.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David S. Richmond purchased 9,780 shares of the business’s stock in a transaction on Monday, July 8th. The shares were bought at an average cost of $3.05 per share, with a total value of $29,829.00. Following the acquisition, the insider now directly owns 179,039 shares of the company’s stock, valued at approximately $546,068.95. The disclosure for this purchase can be found here. Insiders purchased 264,789 shares of company stock valued at $779,198 in the last ninety days. 3.90% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the business. Quantamental Technologies LLC grew its holdings in Rockwell Medical by 194.3% during the first quarter. Quantamental Technologies LLC now owns 5,301 shares of the company’s stock valued at $30,000 after purchasing an additional 3,500 shares during the period. BNP Paribas Arbitrage SA grew its holdings in Rockwell Medical by 5,456.7% during the first quarter. BNP Paribas Arbitrage SA now owns 9,891 shares of the company’s stock valued at $56,000 after purchasing an additional 9,713 shares during the period. Marshall Wace LLP bought a new stake in Rockwell Medical during the first quarter valued at about $57,000. Greenleaf Trust bought a new stake in Rockwell Medical during the second quarter valued at about $36,000. Finally, Royal Bank of Canada grew its holdings in Rockwell Medical by 61.7% during the second quarter. Royal Bank of Canada now owns 12,125 shares of the company’s stock valued at $37,000 after purchasing an additional 4,625 shares during the period. 25.32% of the stock is owned by institutional investors and hedge funds.

Shares of Rockwell Medical stock traded down $0.08 on Friday, reaching $2.91. The company’s stock had a trading volume of 210,337 shares, compared to its average volume of 353,952. The company has a quick ratio of 2.99, a current ratio of 3.25 and a debt-to-equity ratio of 0.06. Rockwell Medical has a 52 week low of $2.19 and a 52 week high of $6.88. The company has a market capitalization of $175.52 million, a price-to-earnings ratio of -6.19 and a beta of 1.47. The firm’s fifty day simple moving average is $2.58 and its two-hundred day simple moving average is $4.03.

Rockwell Medical (NASDAQ:RMTI) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.02). Rockwell Medical had a negative return on equity of 143.68% and a negative net margin of 52.11%. The firm had revenue of $14.85 million during the quarter, compared to the consensus estimate of $16.42 million. As a group, research analysts predict that Rockwell Medical will post -0.64 EPS for the current year.

Rockwell Medical Company Profile

Rockwell Medical, Inc operates as a specialty pharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.

Read More: How to invest in blue-chip stocks

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.